Seres Therapeutics Announces Leadership Transition

Core Insights - Seres Therapeutics has appointed Thomas DesRosier and Marella Thorell as co-CEOs, succeeding Eric Shaff who will remain a Director on the Board [1][3] - The company is actively engaging with multiple parties for potential business development and partnerships to secure additional capital for the advancement of SER-155 and other live biotherapeutic candidates [1][2] Leadership Transition - Eric Shaff is stepping down after a decade, during which he led significant advancements including the first FDA-approved oral microbiome therapy [3] - Thomas DesRosier and Marella Thorell bring extensive experience in biopharma, with DesRosier previously serving as Chief Legal Officer and Thorell as Chief Financial Officer [4][6] Product Development - SER-155 has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT, showing a 77% relative risk reduction in a Phase 1b study [2][7] - The company aims to leverage its live biotherapeutics platform to address various inflammatory and immune diseases, including ulcerative colitis and Crohn's disease [2][7] Strategic Focus - Seres is focused on advancing its pipeline, particularly SER-155, and is exploring various deal structures to enhance its capital resources [2][7] - The company intends to evaluate SER-155 in other medically vulnerable populations, including cancer patients and organ transplant recipients [7]